Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Future Horizons in Lung Cancer

Sorry, this item is currently unavailable.

Published: 5 Oct 2016

Views: 1647

Rating:

Save

Prof Gordon McVie - King's College London, London, UK

Prof McVie presents us with the arguments against using PDL1 and other biomarkers for selecting patients for immune checkpoint therapies, during the Controversies in NSCLC session at the Future Horizons in Lung Cancer meeting.

Related Videos

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India

Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC ( Dr Joshua Sabari, Dr Enriqueta Felip and Dr Alex Spira )

Topics under discussion at the WCLC 2022 presidential symposium

Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain

Topics under discussion at the WCLC 2022 presidential symposium ( Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )

EGFR testing: Best practice for NSCLC patients with exon 20 insertions

Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari

EGFR testing: Best practice for NSCLC patients with exon 20 insertions ( Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari )

More from ecancer